Periodic Reporting for period 1 - GATBIO NEXT (GATBIO NEXT: advancing GRT's 1st oral biologic - GB-AF-004 - to clinical demonstration and out-licensing)
Berichtszeitraum: 2023-06-01 bis 2024-05-31
GAT Biosciences S.L. (GATBIO) is a preclinical stage Biotech SME developing next generation of accessible and non-injected (oral) biopharmaceuticals through proprietary and sustainable microalgal biofactories. Our first candidate is GB-AF-004, an anti-inflammatory biologic for the oral treatment of Inflammatory Bowel Diseases (IBDs). GB-AF-004 has the potential to highly impact the quality of life of millions of IBD’s patients worldwide as an affordable, low toxicity and long-term efficacy therapy for Ulcerative Colitis and Crohn's patients.
GATBIO’s WomenTechEu Project has explored the best therapeutic positioning for GB-AF-004, based on a deep analysis of current therapeutic options for IBD and their limitations, working in collaboration with leaders of opinion in the clinical management of IBD.
Biologic anti-inflammatory therapies have already proven to be highly effective treatments for the induction and remission control of IBD's flares. Still, all available anti-inflammatory biologics are administered by injection and their systemic administration is related to site-effects and middle-terms loss of efficacy. GB-AF-004, a new class of anti-inflammatory antibody of enhanced properties to harsh intestinal atmosphere, has the potential to become the first oral anti-inflammatory biologic for IBDs management, acting specifically and locally in the damaged intestinal tissue without systemic immunosuppression and for long-term non-invasive, accessible and affordable treatments. IBDs includes a range of chronic and painful autoimmune diseases affecting locally the intestine, affecting patients from their youth and throughout life and of unknown causes. More than 10 million people are affected by IBD.